AA
Adrian Adams
COB, CEO and PresidentDirector

Adrian Adams insider trades: Impel Pharmaceuticals (IMPL) stock buys and sales

COB, CEO and President, Impel Pharmaceuticals Last trade Aug 18, 2021 71 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
12
Open-market trades
since 2005
13
Companies
last trade 2021

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Adrian reports to the SEC

and 7 more companies

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 18, 2021IMPL↑ Buy$280K
Jun 15, 2020ACRX↑ Buy$129K
Nov 20, 2019AKBA↑ Buy$171K
Mar 15, 2017ARLZ↑ Buy$1.2M
Nov 12, 2015POZN↑ Buy$6.6M
Dec 5, 2014AUXL↓ Sell$1.4M
May 28, 2013ACRX↑ Buy$614K
May 27, 2008SEPR↑ Buy$1.0M
Aug 16, 2005KOSP↓ Sell$589K
Jul 19, 2005KOSP↓ Sell$623K
Jun 21, 2005KOSP↓ Sell$473K
May 17, 2005KOSP↓ Sell$384K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Adrian Adams's insider trades

Adrian Adams is COB, CEO and President at Impel Pharmaceuticals (IMPL). Since May 17, 2005, Adrian has reported 7 open-market purchases worth $10.0M and 5 sales worth $3.4M on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (50 filings), other transactions (7 filings), shares returned to the company (4 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IMPL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.